TY  - JOUR
AU  - Kovač, Mirjana
AU  - Mitić, Gorana
AU  - Milenković, Marija
AU  - Basarić, Dusica
AU  - Tomić, Branko
AU  - Marković, Olivera
AU  - Zdravković, Marija
AU  - Ignjatović, Vera
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1516
AB  - Background: Coagulation dysfunction represents a serious complication in patients during the COVID-19 infec-tion, while fulminant thrombotic complications emerge as critical issues in individuals with severe COVID-19. In addition to a severe clinical presentation, comorbidities and age significantly contribute to the development of thrombotic complications in this disease. However, there is very little data on association of congenital thrombophilia and thrombotic events in the setting of COVID-19. Our study aimed to evaluate the risk of COVID-19 associated thrombosis in patients with congenital thrombophilia. Methods: This prospective, case-control study included patients with confirmed COVID-19 infection, followed 6 months post-confirmation. The final outcome was a symptomatic thrombotic event. In total, 90 COVID-19 pa-tients, 30 with known congenital thrombophilia and 60 patients without thrombophilia within the period July 2020-November 2021, were included in the study. Evaluation of hemostatic parameters including FVIII activity and D-dimer was performed for all patients at 1 month, 3 months and 6 months post-COVID-19 diagnosis. Results: Symptomatic thrombotic events were observed in 7 out of 30 (23 %) COVID-19 patients with throm-bophilia, and 12 out of 60 (20 %) without thrombophilia, P = 0.715. In addition, the two patient groups had comparable localization of thrombotic events, time to thrombotic event, effect of antithrombotic treatment and changes in FVIII activity, while D-dimer level were significantly increased in patients without thrombophilia. Conclusion: Our findings suggest that patients with congenital thrombophilia, irrespective of their age, a mild clinical picture and absence of comorbidities, should receive anticoagulant prophylaxis, adjusted based on the specific genetic defect.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Thrombosis Research
T1  - Thrombosis risk assessment in patients with congenital thrombophilia during COVID-19 infection
EP  - 156
SP  - 151
VL  - 218
DO  - 10.1016/j.thromres.2022.08.020
ER  - 

@article{
author = "Kovač, Mirjana and Mitić, Gorana and Milenković, Marija and Basarić, Dusica and Tomić, Branko and Marković, Olivera and Zdravković, Marija and Ignjatović, Vera",
year = "2022",
abstract = "Background: Coagulation dysfunction represents a serious complication in patients during the COVID-19 infec-tion, while fulminant thrombotic complications emerge as critical issues in individuals with severe COVID-19. In addition to a severe clinical presentation, comorbidities and age significantly contribute to the development of thrombotic complications in this disease. However, there is very little data on association of congenital thrombophilia and thrombotic events in the setting of COVID-19. Our study aimed to evaluate the risk of COVID-19 associated thrombosis in patients with congenital thrombophilia. Methods: This prospective, case-control study included patients with confirmed COVID-19 infection, followed 6 months post-confirmation. The final outcome was a symptomatic thrombotic event. In total, 90 COVID-19 pa-tients, 30 with known congenital thrombophilia and 60 patients without thrombophilia within the period July 2020-November 2021, were included in the study. Evaluation of hemostatic parameters including FVIII activity and D-dimer was performed for all patients at 1 month, 3 months and 6 months post-COVID-19 diagnosis. Results: Symptomatic thrombotic events were observed in 7 out of 30 (23 %) COVID-19 patients with throm-bophilia, and 12 out of 60 (20 %) without thrombophilia, P = 0.715. In addition, the two patient groups had comparable localization of thrombotic events, time to thrombotic event, effect of antithrombotic treatment and changes in FVIII activity, while D-dimer level were significantly increased in patients without thrombophilia. Conclusion: Our findings suggest that patients with congenital thrombophilia, irrespective of their age, a mild clinical picture and absence of comorbidities, should receive anticoagulant prophylaxis, adjusted based on the specific genetic defect.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Thrombosis Research",
title = "Thrombosis risk assessment in patients with congenital thrombophilia during COVID-19 infection",
pages = "156-151",
volume = "218",
doi = "10.1016/j.thromres.2022.08.020"
}

Kovač, M., Mitić, G., Milenković, M., Basarić, D., Tomić, B., Marković, O., Zdravković, M.,& Ignjatović, V.. (2022). Thrombosis risk assessment in patients with congenital thrombophilia during COVID-19 infection. in Thrombosis Research
Pergamon-Elsevier Science Ltd, Oxford., 218, 151-156.
https://doi.org/10.1016/j.thromres.2022.08.020

Kovač M, Mitić G, Milenković M, Basarić D, Tomić B, Marković O, Zdravković M, Ignjatović V. Thrombosis risk assessment in patients with congenital thrombophilia during COVID-19 infection. in Thrombosis Research. 2022;218:151-156.
doi:10.1016/j.thromres.2022.08.020 .

Kovač, Mirjana, Mitić, Gorana, Milenković, Marija, Basarić, Dusica, Tomić, Branko, Marković, Olivera, Zdravković, Marija, Ignjatović, Vera, "Thrombosis risk assessment in patients with congenital thrombophilia during COVID-19 infection" in Thrombosis Research, 218 (2022):151-156,
https://doi.org/10.1016/j.thromres.2022.08.020 . .